申请人:Takeda Chemical Industries, Ltd.
公开号:US04197298A1
公开(公告)日:1980-04-08
7-[2-(2-aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]cephalosporanic acid derivatives of the formula; ##STR1## wherein R.sup.1 NH is an amino group which may optionally be protected; COOR.sup.2 is a carboxyl group which may optionally be esterified; X is oxygen, sulfur or an imino group which may optionally be substituted; B is hydrogen or a hydroxyl, amino, thiol or hydrocarbon group which may optionally be substituted, or a salt thereof, are novel, .beta.-lactamase-resistant and low-toxicity compounds which display excellent activity against a broad spectrum of microorganisms including Gram-negative bacteria such as Escherichia coli, Serratia marcescens, Proteus rettgeri, Enterobacter cloacae, Citrobacter freundii. Thus, these compounds can be used for antibacterial agents in therapeutical purpose.
本发明涉及一种7-[2-(2-氨基噻唑-4-基)-2-(syn)-甲氧基亚胺基]头孢菌素酸衍生物,其化学式为:##STR1##其中,R.sup.1 NH为氨基,可以选择性地被保护;COOR.sup.2为羧基,可以选择性地被酯化;X为氧、硫或亚胺基,可以选择性地被取代;B为氢或羟基、氨基、硫醇或碳氢基团,可以选择性地被取代,或其盐。这些新颖的β-内酰胺酶抗性和低毒性化合物对包括大肠杆菌、马赛氏菌、雷特格氏变形杆菌、克雷伯氏菌、弗氏柠檬酸杆菌在内的广谱微生物表现出出色的活性。因此,这些化合物可以作为治疗用抗菌剂。